Hoppen takes a new step forward

Back Published on 22/06/2023

Extens is delighted to welcome Après-demain to support Hoppen's strategic development.

After 4 years marked by accelerated organic and external growth, Hoppen has established itself as the French leader in phygital support for patients and healthcare establishments, reducing the workload of caregivers.

A key player in its market and among the recent winners of the French Tech 2030 program, the company is taking a new step forward with the additional support of Après-demain, the parent company of Debiopharm™, a life sciences company, to accelerate its growth plan in Europe and consolidate its market leadership in digital solutions for patients before, during and after hospitalization.

This announcement testifies to the Group's attractiveness, at a time when the company wishes to accelerate its strategic development at every stage of the patient journey.

In perfect alignment with the Group's strategy, Après-demain, with its in-depth knowledge of the healthcare sector, joins forces with existing investors Extens and Geneo. It also validates the relevance of Hoppen's positioning within a rapidly changing sector, in which the Group will continue to develop its expertise in the patient pathway and the continuous improvement (thanks to digital solutions combined with on-site personnel) of hospital operations and post-hospital follow-up, while drastically reducing the drudgery of nursing staff by giving them up to 30% more time for their core business: care.

Already present in several European countries (Belgium, Switzerland), as well as in the Middle East, the Group intends to actively pursue its development in Europe, conquer new markets, and become the European leader in patient care in each of these countries.
« Hoppen, the French leader in the digital transformation of healthcare institutions, aims to become a key international player. its development is a perfect illustration of Extens' investment thesis and desire to have an impact on caregivers and patients. We are delighted to welcome Après-Demain, with whom we share a common vision and values. »